å€è§çãªãã€ãªå»è¬åäŒæ¥ã§ãã Theravance Biopharma, Inc. ã¯ãç±³åœããšãŒããããã¢ãžã¢ã§èåšéžæçå»è¬åã®çºèŠãéçºãåååãè¡ã£ãŠããŸããå瀟ã¯ãæ
¢æ§é塿§èºçŸæ£ (COPD) ã®æ²»çã«äœ¿çšãããã1 æ¥ 1 ååŽé§åŒã®é·æéäœçšåã ã¹ã«ãªã³æ®æè¬ YUPELRI ãæäŸããŠããŸããå瀟ã®è£œåããŒããã©ãªãªã«ã¯ãé¢ç¯ãªãŠããã骚é«ç·ç¶çãæœ°çæ§å€§è
žçã®ã»ããæœ°çæ§å€§è
žçãã¯ããŒã³ç
ãªã©ã®ããŸããŸãªççæ§è
žçŸæ£ã®æ²»çè¬ãšããŠç¬¬ IIb/III çžèšåºè©Šéšãè¡ãããŠããè
žç®¡éžæçæ±ã€ãã¹ãããŒãŒ (JAK) é»å®³å€ã§ããã€ãŒã³ã·ããããå«ãŸããŠããŸããããã«ãå瀟ã®è£œåããŒããã©ãªãªã«ã¯ãç¥çµæ§èµ·ç«æ§äœè¡å§ã«å¯Ÿãã第 III çžè©Šéšãå®äºããæ²»éšäžã®ãã«ãšããããªã³ååã蟌ã¿é»å®³å€ã§ããã¢ã³ãã¬ããã»ãã³ãå«ãŸããŠããŸãã TD-8236ã¯ãççæ§çŸæ£ã®æ²»çè¬ãšããŠç¬¬IIçžèšåºè©Šéšäžã®ãåžå
¥åŒã®èºéžæçæ±JAKé»å®³å€ãTD-5202ã¯ãççæ§è
žçŸæ£ã®æ²»çè¬ãšããŠç¬¬Içžèšåºè©Šéšäžã®ãçµå£æäžã®è
žç®¡éžæçäžå¯éçJAK3é»å®³å€ã§ããããã«ãCOPDã®æ²»çè¬TRELEGYãæ¶å管éåé害ã®çµå£æ²»éšè¬Velusetragãæ¶å管éåéå®³ã®æ²»çè¬éžæç5-HT4äœåè¬ãæäŸããŠããŸãããã¡ã€ã¶ãŒç€Ÿããã¢ããªã¹ç€Ÿãã€ã³ã»ã³ã»ãã€ãªããã¯ç€Ÿãã¢ã«ãã¡ã·ã°ãç€ŸãæŠç°è¬åå·¥æ¥æ ªåŒäŒç€Ÿãšã©ã€ã»ã³ã¹å¥çŽããã³ææºå¥çŽãçµãã§ããŸããå瀟ã¯2013幎ã«èšç«ãããã±ã€ãã³è«žå³¶ã®ãžã§ãŒãžã¿ãŠã³ã«æ ç¹ã眮ããŠããŸãã